Mutations in DNMT3A (the product of which catalyzes de novo DNA methylation), TET2 (responsible for regulated demethylation), and ASXL1 (involved in chromatin regulation), are the most frequently described mutations in clonal hematopoiesis, including clonal hematopoiesis of indeterminate potential (CHIP) and myeloid malignancies such as myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML) (23–25). This evidence concerns the gene ASXL1 and acute myeloid leukemia.